Short answer
Niagen Bioscience, Inc. (NAGE) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $31M (up 3.3% year over year) with net income of $6M.
Q1 2026 key financials · XBRL
- Revenue
- $31M
- +3.3% YoY
- Net income
- $6M
- +24.8% YoY
- Operating margin
- 5.0%
- Gross margin
- 63.5%
- EPS (diluted)
- $0.07
- +16.7% YoY
Source: XBRL data from the Niagen Bioscience, Inc. (NAGE) Q1 2026 10-Q on SEC EDGAR. USD.
Niagen Bioscience, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $31.474M, up 3% YoY from $30.481M
- Consumer Products revenue $22.413M, up 4% YoY; Ingredients $8.564M, up 5%
- Gross margin 63.5% vs 63.4% YoY; sales and marketing 30.7% of revenue vs 26.6%
- Net income $6.318M vs $5.063M; gain on segment sale $4.8M
- Cash $66.5M, including $66.4M unrestricted; sale proceeds approximately $6.0M
Risk Factors
- Newly emphasized competition risk: FDA’s September 2025 determination allowing NMN marketing as a dietary ingredient
- Competitive pressure: Larger rivals may underprice products, reducing revenue and increasing losses
- Regulatory risk: Changing dietary-supplement rules could increase compliance costs or reduce product demand
- Operational risk: Reliance on W.R. Grace as the single NRC supplier creates supply-disruption exposure
- Financial risk: Potential capital needs within twelve months may cause dilution or unfavorable financing terms
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Niagen Bioscience, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.